Trial Profile
A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Cabazitaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CheckMate 650
- Sponsors Bristol-Myers Squibb
- 05 Jan 2024 Planned End Date changed from 6 Oct 2026 to 31 May 2024.
- 18 Feb 2023 Results (n=259) assessing safety and efficacy of alternative NIVO+IPI dosing regimens vs IPI alone vs cabazitaxel (CABA) in pts with post-CT mCRPC presented at the 2023 Genitourinary Cancers Symposium
- 06 Sep 2022 Planned End Date changed from 8 Oct 2026 to 6 Oct 2026.